Natural compounds in epigenetics: A current view

Food and Chemical Toxicology

Volumn 73, Issue , 2014, Pages 71-83

  Miceli, Marco ^a,b   Bontempo, Paola ^a   Nebbioso, Angela ^a   Altucci, Lucia ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Cancer; Epigenetics; Natural compounds

Indexed keywords

11,11' DIDEOXYVERTICILLIN A; 2 PROPENE 1 THIOL; 3 3' DIINDOLYLMETHANE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; CAROTENOID; CHETOCIN; CHETOMIN; CURCUMIN; DIALLYL DISULFIDE; DNA; EPIPOLYTHIODIOXOPIPERAZINE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; GLIOTOXIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; LYCOPENE; NATURAL PRODUCT; PHENETHYL ISOTHIOCYANATE; POLYPHENOL; PSAMMAPLIN A; QUERCETIN; ROMIDEPSIN; SULFORAPHANE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; URSODEOXYCHOLIC ACID; 3,3' DIINDOLYLMETHANE; ACETYLSALICYLIC ACID; CHAETOCIN; ELLAGITANNIN; EPIGALLOCATECHIN GALLATE; FLAVONE; GARGINOL; GENISTEIN; MITOCHONDRIAL RNA; RESVERATROL; SULINDAC; UVI 5008; BIOLOGICAL PRODUCT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON CANCER; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DNA MODIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ISOLATION; DRUG STRUCTURE; DRUG USE; EPIGENETICS; HISTONE ACETYLATION; HISTONE DEMETHYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; NONHUMAN; REVIEW; SOLID TUMOR; APOPTOSIS; AUTOPHAGY; CANCER GENETICS; CARCINOGENESIS; CATALYSIS; CELL CYCLE ARREST; COLORECTAL CANCER; DNA METHYLATION; HIGH THROUGHPUT SCREENING; MOLECULAR DYNAMICS; ONCOGENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; UBIQUITINATION; GENETIC EPIGENESIS;

BIOLOGICAL PRODUCTS; EPIGENESIS, GENETIC;

EID: 84906733953     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.08.005     Document Type: Review

References (154)

1. Akare S., Jean-Louis S., Chen W., Wood D.J., Powell A.A., Martinez J.D. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int. J. Cancer 2006, 119:2958-2969.
2. Albert I., Mavrich T.N., Tomsho L.P., Qi J., Zanton S.J., Schuster S.C., Pugh B.F. Translational and rotational settings of H2A.Z nucleosomes across the Saccharomyces cerevisiae genome. Nature 2007, 446:572-576.
3. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
4. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11:384-400.
5. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., Kundu T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279:33716-33726.
6. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Baud M.G., Leiser T., Haus P., Samlal S., Wong A.C., Wood R.J., Petrucci V., Gunaratnam M., Hughes S.M., Buluwela L., Turlais F., Neidle S., Meyer-Almes F.J., White A.J., Fuchter M.J. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J. Med. Chem. 2012, 55:1731-1750.
9. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
10. Becker A., Allmann L., Hofstatter M., Casa V., Weber P., Lehmkuhl A., Herce H.D., Cardoso M.C. Direct homo- and hetero-interactions of MeCP2 and MBD2. PLoS ONE 2013, 8:e53730.
11. Benedetti R., Conte M., Altucci L. Targeting HDACs in diseases: where are we?. Antioxid. Redox Signal 2014, 10.
12. Bhatnagar N., Li X., Chen Y., Zhou X., Garrett S.H., Guo B. 3,3'-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev. Res. (Phila) 2009, 2:581-589.
13. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321:209-213.
14. Bischoff S.C. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:733-740.
15. Black J.C., Van Rechem C., Whetstine J.R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 2012, 48:491-507.
16. Bontempo P., Doto A., Miceli M., Mita L., Benedetti R., Nebbioso A., Veglione M., Rigano D., Cioffi M., Sica V., Molinari A.M., Altucci L. Psidium guajava L. anti-neoplastic effects: induction of apoptosis and cell differentiation. Cell Prolif. 2012, 45:22-31.
17. Bontempo P., Mita L., Miceli M., Doto A., Nebbioso A., De Bellis F., Conte M., Minichiello A., Manzo F., Carafa V., Basile A., Rigano D., Sorbo S., Castaldo Cobianchi R., Schiavone E.M., Ferrara F., De Simone M., Vietri M., Cioffi M., Sica V., Bresciani F., de Lera A.R., Altucci L., Molinari A.M. Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. Int. J. Biochem. Cell Biol. 2007, 39:1902-1914.
18. Brait M., Sidransky D. Cancer epigenetics: above and beyond. Toxicol. Mech. Methods 2011, 21:275-288.
19. Brockdorff N. Noncoding RNA and Polycomb recruitment. RNA 2013, 19:429-442.
20. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074.
21. Carafa V., Miceli M., Altucci L., Nebbioso A. Histone deacetylase inhibitors: a patent review (2009-2011). Expert Opin. Ther. Pat. 2013, 23:1-17.
22. Carafa V., Nebbioso A., Altucci L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge and patenting of anti-cancer actions. Recent Pat. Anti-Cancer Drug Discovery 2011, 6:131-145.
23. Carrozza M.J., Li B., Florens L., Suganuma T., Swanson S.K., Lee K.K., Shia W.J., Anderson S., Yates J., Washburn M.P., Workman J.L. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell 2005, 123:581-592.
24. Chalabi N., Delort L., Le Corre L., Satih S., Bignon Y.J., Bernard-Gallon D. Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics 2006, 7:663-672.
25. Chalabi N., Delort L., Satih S., Dechelotte P., Bignon Y.J., Bernard-Gallon D.J. Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR. J. Histochem. Cytochem. 2007, 55:877-883.
26. Chalabi N., Satih S., Delort L., Bignon Y.J., Bernard-Gallon D.J. Expression profiling by whole-genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure. Biochim. Biophys. Acta 2007, 1769:124-130.
27. Chen J., Kang J.H. Quercetin and trichostatin A cooperatively kill human leukemia cells. Pharmazie 2005, 60:856-860.
28. Chen Q., Chen Y., Bian C., Fujiki R., Yu X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 2013, 493:561-564.
29. Cheung K.L., Kong A.N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 2010, 12:87-97.
30. Choi K.C., Jung M.G., Lee Y.H., Yoon J.C., Kwon S.H., Kang H.B., Kim M.J., Cha J.H., Kim Y.J., Jun W.J., Lee J.M., Yoon H.G. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009, 69:583-592.
31. Choi W.I., Jeon B.N., Yoon J.H., Koh D.I., Kim M.H., Yu M.Y., Lee K.M., Kim Y., Kim K., Hur S.S., Lee C.E., Kim K.S., Hur M.W. The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation. Nucleic Acids Res. 2013, 41:6403-6420.
32. Choy J.S., Wei S., Lee J.Y., Tan S., Chu S., Lee T.H. DNA methylation increases nucleosome compaction and rigidity. J. Am. Chem. Soc. 2010, 132:1782-1783.
33. Christman J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21:5483-5495.
34. Codd R., Braich N., Liu J., Soe C.Z., Pakchung A.A. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int. J. Biochem. Cell Biol. 2009, 41:736-739.
35. Cohen I., Poreba E., Kamieniarz K., Schneider R. Histone modifiers in cancer: friends or foes?. Genes Cancer 2011, 2:631-647.
36. Conte M., Altucci L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin. Cancer Res. 2012, 18:5526-5534.
37. Cook K.M., Hilton S.T., Mecinovic J., Motherwell W.B., Figg W.D., Schofield C.J. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J. Biol. Chem. 2009, 284:26831-26838.
38. Copeland R.A., Solomon M.E., Richon V.M. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 2009, 8:724-732.
39. Costa Y., Ding J., Theunissen T.W., Faiola F., Hore T.A., Shliaha P.V., Fidalgo M., Saunders A., Lawrence M., Dietmann S., Das S., Levasseur D.N., Li Z., Xu M., Reik W., Silva J.C., Wang J. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013, 495:370-374.
40. D'Archivio M., Filesi C., Vari R., Scazzocchio B., Masella R. Bioavailability of the polyphenols: status and controversies. Int. J. Mol. Sci. 2010, 11:1321-1342.
41. Daniel F.I., Cherubini K., Yurgel L.S., de Figueiredo M.A., Salum F.G. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011, 117:677-687.
42. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133:2485S-2493S.
43. Dell'aversana C., Altucci L. MiRNA-mediated deregulation in leukemia. Front Genet. 2012, 3:252.
44. Engin H.B., Gursoy A., Nussinov R., Keskin O. Network-based strategies can help mono- and poly-pharmacology drug discovery: a systems biology view. Curr. Pharm. Des. 2013.
45. Estecio M.R., Gallegos J., Vallot C., Castoro R.J., Chung W., Maegawa S., Oki Y., Kondo Y., Jelinek J., Shen L., Hartung H., Aplan P.D., Czerniak B.A., Liang S., Issa J.P. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res. 2010, 20:1369-1382.
46. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv. Exp. Med. Biol. 2003, 532:39-49.
47. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br. J. Cancer 2006, 94:179-183.
48. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
49. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11:7033-7041.
50. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63:7563-7570.
51. Feher M., Schmidt J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 2003, 43:218-227.
52. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440.
53. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
54. Franci G., Miceli M., Altucci L. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics 2010, 2:731-742.
55. Fullgrabe J., Kavanagh E., Joseph B. Histone onco-modifications. Oncogene 2011, 30:3391-3403.
56. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62:4916-4921.
57. Garcia J., Franci G., Pereira R., Benedetti R., Nebbioso A., Rodriguez-Barrios F., Gronemeyer H., Altucci L., de Lera A.R. Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. Bioorg. Med. Chem. 2011, 19:3637-3649.
58. Gardiner D.M., Waring P., Howlett B.J. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology 2005, 151:1021-1032.
59. Gardner K.E., Allis C.D., Strahl B.D. Operating on chromatin, a colorful language where context matters. J. Mol. Biol. 2011, 409:36-46.
60. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 2010, 62:919-930.
61. Goldberg A.D., Banaszynski L.A., Noh K.M., Lewis P.W., Elsaesser S.J., Stadler S., Dewell S., Law M., Guo X., Li X., Wen D., Chapgier A., DeKelver R.C., Miller J.C., Lee Y.L., Boydston E.A., Holmes M.C., Gregory P.D., Greally J.M., Rafii S., Yang C., Scambler P.J., Garrick D., Gibbons R.J., Higgs D.R., Cristea I.M., Urnov F.D., Zheng D., Allis C.D. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010, 140:678-691.
62. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481-514.
63. Grabowski K., Baringhaus K.H., Schneider G. Scaffold diversity of natural products: inspiration for combinatorial library design. Natl. Prod. Rep. 2008, 25:892-904.
64. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1:143-145.
65. Gu P., Xu X., Le Menuet D., Chung A.C., Cooney A.J. Differential recruitment of methyl CpG-binding domain factors and DNA methyltransferases by the orphan receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem Cells 2011, 29:1041-1051.
66. Gupta K., Panda D. Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry 2002, 41:13029-13038.
67. Harfe B.D. MicroRNAs in vertebrate development. Curr. Opin. Genet. Dev. 2005, 15:410-415.
68. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 2012, 13:679-692.
69. Huang J., Plass C., Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets 2011, 12:1925-1956.
70. Ibanez de Caceres I., Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clin. Transl. Oncol. 2007, 9:429-437.
71. Jacob C. A scent of therapy: pharmacological implications of natural products containing redox-active sulfur atoms. Natl. Prod. Rep. 2006, 23:851-863.
72. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
73. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
74. Jian L. Soy, isoflavones, and prostate cancer. Mol. Nutr. Food Res. 2009, 53:217-226.
75. Jin B., Robertson K.D. DNA methyltransferases, DNA damage repair, and cancer. Adv. Exp. Med. Biol. 2013, 754:3-29.
76. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
77. Jurkowski T.P., Meusburger M., Phalke S., Helm M., Nellen W., Reuter G., Jeltsch A. Human DNMT2 methylates tRNA(Asp) molecules using a DNA methyltransferase-like catalytic mechanism. RNA 2008, 14:1663-1670.
78. Kang S.K., Cha S.H., Jeon H.G. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 2006, 15:165-174.
79. Kapranov P., St Laurent G., Raz T., Ozsolak F., Reynolds C.P., Sorensen P.H., Reaman G., Milos P., Arceci R.J., Thompson J.F., Triche T.J. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol. 2010, 8:149.
80. Keating G.M. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2012, 72:1111-1136.
81. Kimura S., Kuramoto K., Homan J., Naruoka H., Ego T., Nogawa M., Sugahara S., Naito H. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. Anticancer Res. 2012, 32:795-798.
82. King-Batoon A., Leszczynska J.M., Klein C.B. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 2008, 49:36-45.
83. Knight R.A., Gostev M., Ilisavskii S., Willis A.E., Melino G., Antonov A.V. Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays. Oncotarget 2014, 5:659-666.
84. Ko M., An J., Bandukwala H.S., Chavez L., Aijo T., Pastor W.A., Segal M.F., Li H., Koh K.P., Lahdesmaki H., Hogan P.G., Aravind L., Rao A. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013, 497:122-126.
85. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4:206-220.
86. Krinner S., Heitzer A.P., Diermeier S.D., Obermeier I., Langst G., Wagner R. CpG domains downstream of TSSs promote high levels of gene expression. Nucleic Acids Res. 2014, 42:3551-3564.
87. Kuck D., Singh N., Lyko F., Medina-Franco J.L. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem. 2010, 18:822-829.
88. Lee C.K., Shibata Y., Rao B., Strahl B.D., Lieb J.D. Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat. Genet. 2004, 36:900-905.
89. Lee W.J., Chen Y.R., Tseng T.H. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol. Rep. 2011, 25:583-591.
90. Li C.H., Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int. J. Biochem. Cell Biol. 2013, 45:1895-1910.
91. Li X., Wu Z., Fu X., Han W. Long noncoding RNAs: insights from biological features and functions to diseases. Med. Res. Rev. 2013, 33:517-553.
92. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
93. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., Edsall L., Antosiewicz-Bourget J., Stewart R., Ruotti V., Millar A.H., Thomson J.A., Ren B., Ecker J.R. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
94. Lucchesi J.C., Kelly W.G., Panning B. Chromatin remodeling in dosage compensation. Annu. Rev. Genet. 2005, 39:615-651.
95. Majid S., Dar A.A., Shahryari V., Hirata H., Ahmad A., Saini S., Tanaka Y., Dahiya A.V., Dahiya R. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010, 116:66-76.
96. Marques C.J., Joao Pinho M., Carvalho F., Bieche I., Barros A., Sousa M. DNA methylation imprinting marks and DNA methyltransferase expression in human spermatogenic cell stages. Epigenetics 2011, 6:1354-1361.
97. Meeran S.M., Ahmed A., Tollefsbol T.O. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenet. 2010, 1:101-116.
98. Meng J., Zhang H.H., Zhou C.X., Li C., Zhang F., Mei Q.B. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol. Rep. 2012, 28:384-388.
99. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
100. Mito Y., Henikoff J.G., Henikoff S. Genome-scale profiling of histone H3.3 replacement patterns. Nat. Genet. 2005, 37:1090-1097.
101. Muller S., Windhof I.M., Maximov V., Jurkowski T., Jeltsch A., Forstner K.U., Sharma C.M., Graf R., Nellen W. Target recognition, RNA methylation activity and transcriptional regulation of the Dictyostelium discoideum Dnmt2-homologue (DnmA). Nucleic Acids Res. 2013, 41:8615-8627.
102. Myzak M.C., Karplus P.A., Chung F.L., Dashwood R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004, 64:5767-5774.
103. Nebbioso A., Carafa V., Benedetti R., Altucci L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 2012, 6:657-682.
104. Nebbioso A., Pereira R., Khanwalkar H., Matarese F., Garcia-Rodriguez J., Miceli M., Logie C., Kedinger V., Ferrara F., Stunnenberg H.G., de Lera A.R., Gronemeyer H., Altucci L. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol. Cancer Ther. 2011, 10:2394-2404.
105. Nishino T., Wang C., Mochizuki-Kashio M., Osawa M., Nakauchi H., Iwama A. Ex vivo expansion of human hematopoietic stem cells by garcinol, a potent inhibitor of histone acetyltransferase. PLoS ONE 2011, 6:e24298.
106. Okuda T., Yoshida T., Hatano T. Ellagitannins as active constituents of medicinal plants. Planta Med. 1989, 55:117-122.
107. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
108. Parker L.P., Taylor D.D., Kesterson J., Metzinger D.S., Gercel-Taylor C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol. 2009, 30:616-621.
109. Payer B., Lee J.T. X chromosome dosage compensation: how mammals keep the balance. Annu. Rev. Genet. 2008, 42:733-772.
110. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 2011, 2011:371832.
111. Petrella A., D'Acunto C.W., Rodriquez M., Festa M., Tosco A., Bruno I., Terracciano S., Taddei M., Paloma L.G., Parente L. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer 2008, 44:740-749.
112. Pina I.C., Gautschi J.T., Wang G.Y., Sanders M.L., Schmitz F.J., France D., Cornell-Kennon S., Sambucetti L.C., Remiszewski S.W., Perez L.B., Bair K.W., Crews P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68:3866-3873.
113. Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., Klut I.M., Knoth H., Rollig C., Schetelig J., Mohr B., Graehlert X., Ehninger G., Bornhauser M., Thiede C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
114. Quideau S., Deffieux D., Douat-Casassus C., Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew. Chem. Int. Ed. Engl. 2011, 50:586-621.
115. Rahman I. Dietary polyphenols mediated regulation of oxidative stress and chromatin remodeling in inflammation. Nutr. Rev. 2008, 66(Suppl 1):S42-S45.
116. Raijmakers R., Zendman A.J., Egberts W.V., Vossenaar E.R., Raats J., Soede-Huijbregts C., Rutjes F.P., van Veelen P.A., Drijfhout J.W., Pruijn G.J. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J. Mol. Biol. 2007, 367:1118-1129.
117. Rao A.V., Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J. Am. Coll. Nutr. 2000, 19:563-569.
118. Rauch T.A., Wu X., Zhong X., Riggs A.D., Pfeifer G.P. A human B cell methylome at 100-base pair resolution. Proc. Natl. Acad. Sci. USA 2009, 106:671-678.
119. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
120. Safe S., Papineni S., Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett. 2008, 269:326-338.
121. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
122. Scaruffi P. The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility. Sci. World J. 2011, 11:340-352.
123. Schwartz S., Meshorer E., Ast G. Chromatin organization marks exon-intron structure. Nat. Struct. Mol. Biol. 2009, 16:990-995.
124. Seidel C., Schnekenburger M., Dicato M., Diederich M. Histone deacetylase modulators provided by Mother Nature. Genes. Nutr. 2012, 7:357-367.
125. Sharif J., Muto M., Takebayashi S., Suetake I., Iwamatsu A., Endo T.A., Shinga J., Mizutani-Koseki Y., Toyoda T., Okamura K., Tajima S., Mitsuya K., Okano M., Koseki H. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007, 450:908-912.
126. Sharp A.J., Stathaki E., Migliavacca E., Brahmachary M., Montgomery S.B., Dupre Y., Antonarakis S.E. DNA methylation profiles of human active and inactive X chromosomes. Genome Res. 2011, 21:1592-1600.
127. Shi X., Sun M., Liu H., Yao Y., Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013, 339:159-166.
128. Smith B.C., Denu J.M. Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta 2009, 1789:45-57.
129. Sun Y., Takada K., Takemoto Y., Yoshida M., Nogi Y., Okada S., Matsunaga S. Gliotoxin analogues from a marine-derived fungus, Penicillium sp., and their cytotoxic and histone methyltransferase inhibitory activities. J. Nat. Prod. 2012, 75:111-114.
130. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
131. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J. Clin. 2010, 60:376-392.
132. Tai K.Y., Shiah S.G., Shieh Y.S., Kao Y.R., Chi C.Y., Huang E., Lee H.S., Chang L.C., Yang P.C., Wu C.W. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 2007, 26:3989-3997.
133. Tan M., Luo H., Lee S., Jin F., Yang J.S., Montellier E., Buchou T., Cheng Z., Rousseaux S., Rajagopal N., Lu Z., Ye Z., Zhu Q., Wysocka J., Ye Y., Khochbin S., Ren B., Zhao Y. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
134. Tan S., Wang C., Lu C., Zhao B., Cui Y., Shi X., Ma X. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 2009, 55:6-10.
135. Tang Y., Chen Y., Jiang H., Nie D. Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ. 2011, 18:602-618.
136. Thakur V.S., Deb G., Babcook M.A., Gupta S. Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. AAPS J. 2014, 16:151-163.
137. Tibodeau J.D., Benson L.M., Isham C.R., Owen W.G., Bible K.C. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid. Redox Signal. 2009, 11:1097-1106.
138. Tilgner H., Nikolaou C., Althammer S., Sammeth M., Beato M., Valcarcel J., Guigo R. Nucleosome positioning as a determinant of exon recognition. Nat. Struct. Mol. Biol. 2009, 16:996-1001.
139. Tsang W.P., Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 2010, 21:140-146.
140. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
141. Veeck J., Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J. Mammary Gland Biol. Neoplasia 2010, 15:5-17.
142. Wade P.A. Methyl CpG-binding proteins and transcriptional repression. BioEssays 2001, 23:1131-1137.
143. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet. 2010, 1:117-136.
144. Wang L.G., Beklemisheva A., Liu X.M., Ferrari A.C., Feng J., Chiao J.W. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol. Carcinog. 2007, 46:24-31.
145. Wang R.H., Zheng Y., Kim H.S., Xu X., Cao L., Luhasen T., Lee M.H., Xiao C., Vassilopoulos A., Chen W., Gardner K., Man Y.G., Hung M.C., Finkel T., Deng C.X. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 2008, 32:11-20.
146. Watanabe M., Adachi S., Matsubara H., Imai T., Yui Y., Mizushima Y., Hiraumi Y., Watanabe K., Kamitsuji Y., Toyokuni S.Y., Hosoi H., Sugimoto T., Toguchida J., Nakahata T. Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation. Int. J. Cancer 2009, 124:55-67.
147. Wei Y.Q., Zhao X., Kariya Y., Fukata H., Teshigawara K., Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res. 1994, 54:4952-4957.
148. Wen B., Wu H., Shinkai Y., Irizarry R.A., Feinberg A.P. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat. Genet. 2009, 41:246-250.
149. Wen X.Y., Wu S.Y., Li Z.Q., Liu Z.Q., Zhang J.J., Wang G.F., Jiang Z.H., Wu S.G. Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother. Res. 2009, 23:778-784.
150. Wutz A. Xist function: bridging chromatin and stem cells. Trends Genet. 2007, 23:457-464.
151. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9:429-439.
152. Yang M., Park J.Y. DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol. Biol. 2012, 863:67-109.
153. Yang X.J., Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 2007, 26:5408-5419.
154. Zamudio N., Bourc'his D. Transposable elements in the mammalian germline: a comfortable niche or a deadly trap?. Heredity 2010, 105:92-104.